Literature DB >> 16051391

Preparation and in vitro anticancer activity of wheat germ agglutinin (WGA)-conjugated PLGA nanoparticles loaded with paclitaxel and isopropyl myristate.

Yun Mo1, Lee-Yong Lim.   

Abstract

The purpose of this study was to develop a novel lectin-conjugated isopropyl myristate (IPM)-incorporated PLGA nanoparticle system (NP) for the local delivery of paclitaxel to the lungs. Wheat germ agglutinin (WGA) was conjugated onto preformed IPM- and paclitaxel-loaded PLGA NPs by a two-step carbodiimide method following comparative uptake studies of Concanavalin A, Ricinus communis-120 and WGA on A549, H1299 and CCL-186 cells. WIT-NP with mean diameter of 331 nm and zeta potential of -4.3 mV were prepared with yield of 66% and paclitaxel encapsulation efficiency of 61%. Particle size was expanded by surface conjugation with WGA, while zeta potential was reduced by the addition of IPM and WGA. In vitro paclitaxel release profile was not affected by WGA but initial drug release was enhanced by adding IPM into the formulation. The WIT-NP showed a burst-release of about 32% of the paclitaxel load within the first 5 h followed by a slow zero-order release of another 7% of the drug load in the next 115 h. Compared with the clinical paclitaxel formulation, paclitaxel-loaded nanoparticles without IPM or WGA, or paclitaxel-loaded nanoparticles with only IPM or WGA, the WIT-NP had superior in vitro cytotoxicity against A549 and H1299 cells. IC50 for WIT-NP after 5 and 24 h incubation with A549 cells were not significantly different (15.5 and 15 microM, respectively) whereas the clinical formulation was not cytotoxic after 5 h but had IC50 of 14 microM after 24 h incubation. WIT-NP exhibited stronger cell-killing effect because of more efficient cellular uptake via WGA-receptor-mediated endocytosis and IPM-facilitated release of paclitaxel from the NPs.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16051391     DOI: 10.1016/j.jconrel.2004.06.024

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  16 in total

1.  Controlling ligand surface density optimizes nanoparticle binding to ICAM-1.

Authors:  Amir Fakhari; Abdulgader Baoum; Teruna J Siahaan; Khoi Ba Le; Cory Berkland
Journal:  J Pharm Sci       Date:  2010-10-04       Impact factor: 3.534

2.  Immunocolloidal targeting of the endocytotic siglec-7 receptor using peripheral attachment of siglec-7 antibodies to poly(lactide-co-glycolide) nanoparticles.

Authors:  Christopher J Scott; Waleed M Marouf; Derek J Quinn; Richard J Buick; Selinda J Orr; Ryan F Donnelly; Paul A McCarron
Journal:  Pharm Res       Date:  2007-08-03       Impact factor: 4.200

3.  Interaction between drug delivery vehicles and cells under the effect of shear stress.

Authors:  M Godoy-Gallardo; P K Ek; M M T Jansman; B M Wohl; L Hosta-Rigau
Journal:  Biomicrofluidics       Date:  2015-06-30       Impact factor: 2.800

4.  Micelles of different morphologies--advantages of worm-like filomicelles of PEO-PCL in paclitaxel delivery.

Authors:  Shenshen Cai; Kandaswamy Vijayan; Debbie Cheng; Eliana M Lima; Dennis E Discher
Journal:  Pharm Res       Date:  2007-06-13       Impact factor: 4.200

Review 5.  Nanoparticles for oral delivery: targeted nanoparticles with peptidic ligands for oral protein delivery.

Authors:  Yeonhee Yun; Yong Woo Cho; Kinam Park
Journal:  Adv Drug Deliv Rev       Date:  2012-11-02       Impact factor: 15.470

6.  Comparing cellular uptake and cytotoxicity of targeted drug carriers in cancer cell lines with different drug resistance mechanisms.

Authors:  Tingjun Lei; Supriya Srinivasan; Yuan Tang; Romila Manchanda; Abhignyan Nagesetti; Alicia Fernandez-Fernandez; Anthony J McGoron
Journal:  Nanomedicine       Date:  2010-11-19       Impact factor: 5.307

7.  Wheat Germ Agglutinin-Conjugated Disulfide Cross-Linked Alginate Nanoparticles as a Docetaxel Carrier for Colon Cancer Therapy.

Authors:  Hock Ing Chiu; Vuanghao Lim
Journal:  Int J Nanomedicine       Date:  2021-04-22

Review 8.  Polylactide-co-glycolide nanoparticles for controlled delivery of anticancer agents.

Authors:  R Dinarvand; N Sepehri; S Manoochehri; H Rouhani; F Atyabi
Journal:  Int J Nanomedicine       Date:  2011-05-27

9.  Anti-DR5 monoclonal antibody-mediated DTIC-loaded nanoparticles combining chemotherapy and immunotherapy for malignant melanoma: target formulation development and in vitro anticancer activity.

Authors:  Baoyue Ding; Xin Wu; Wei Fan; Zhaoyong Wu; Jing Gao; Wei Zhang; Lulu Ma; Wang Xiang; Quangang Zhu; Jiyong Liu; Xueying Ding; Shen Gao
Journal:  Int J Nanomedicine       Date:  2011-09-15

Review 10.  Orally Administrable Therapeutic Nanoparticles for the Treatment of Colorectal Cancer.

Authors:  Kangkang Ying; Bingjun Bai; Xing Gao; Yuzi Xu; Hangxiang Wang; Binbin Xie
Journal:  Front Bioeng Biotechnol       Date:  2021-07-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.